Miltefosine for new world cutaneous leishmaniasis

Clinical Infectious Diseases

Volumn 38, Issue 9, 2004, Pages 1266-1272

  Soto, J ^a   Arana, B A ^d   Tolado, J ^a   Rizzo, N ^d   Vega, J C ^b   Diaz, A ^d   Luz, M ^a   Gutierrez, P ^a   Arboleda, M ^c   Berman, J D ^f,g   Junge, K ^e   Engel, J ^e   Sindermann, H ^e,h  

^a Consorcio de Invest Bioclinicas ^*  (Colombia)

^b Fundacion Fader   (Colombia)

^c Instituto Colombiano de Medicina Tropical   (Colombia)

^d University del Valle of Guatemala   (Guatemala)

^e Baxter Oncology GmbH   (Germany)

^f Zentaris GmbH and Baxter Oncology   (United States)

^g NATIONAL INSTITUTES OF HEALTH   (United States)

^h Zentaris GmbH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

MILTEFOSINE; PLACEBO; ANTIPROTOZOAL AGENT; DRUG DERIVATIVE; PHOSPHORYLCHOLINE;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COLOMBIA; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG TOLERABILITY; FEMALE; GUATEMALA; HUMAN; LEISHMANIA BRAZILIENSIS; LEISHMANIA MEXICANA; LEISHMANIA PANAMENSIS; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SKIN LEISHMANIASIS; ANIMAL; DRUG TOLERANCE; LEISHMANIA; ORAL DRUG ADMINISTRATION; PATIENT COMPLIANCE; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ADULT; ANIMALS; ANTIPROTOZOAL AGENTS; COLOMBIA; DOUBLE-BLIND METHOD; DRUG TOLERANCE; FEMALE; GUATEMALA; HUMANS; LEISHMANIA; LEISHMANIASIS, CUTANEOUS; MALE; PATIENT COMPLIANCE; PHOSPHORYLCHOLINE; TREATMENT OUTCOME;

EID: 2342538350     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/383321     Document Type: Article

References (28)

1. Kreutzer RD, Semko ME, Hendricks LD, et al. Identification of Leishmania spp by multiple isozyme analysis. Am J Trop Med Hyg 1983; 32:703-15.
2. Chico ME, Guderian RH, Cooper PJ, Armijos R, Grogl M. Evaluation of a direct immunofluorescent antibody (DIFMA) test using Leishmania genus-specific monoclonal antibody in the routine diagnosis of cutaneous leishmaniasis. Rev Soc Bras Med Trop 1995; 28:99-103.
3. Gangneux J-P, Menotti J, Lorenzo F, et al. Prospective value of PCR amplification and sequencing for diagnosis and typing of Old World Leishmania infections in an area of nonendemicity. J Clin Microbiol 2003; 41:1419-22.
4. Herwaldt BL, Berman JD. Recommendations for treating leishmaniasis with sodium stibogluconate (Pentostam) and review of pertinent clinical studies. Am J Trop Med Hyg 1992; 46:296-306.
5. Arana BA, Navin TR, Arana FE, et al. Efficacy of a short course (10 days) of high-dose meglumine antimonate with or without interferon-gamma in treating cutaneous leishmaniasis in Guatemala. Clin Infect Dis 1994; 18:381-4.
6. Oliveira-Neto MP, Schubach A, Mattos M, Goncalves-Costa SC, Pirmez C. A low-dose antimony treatment in 159 patients with American cutaneous leishmaniasis: extensive follow-up studies (up to 10 years). Am J Trop Med Hyg 1997; 57:651-5.
7. Velez I, Agudelo S, Hendrickx E, et al. Inefficacy of Allopurinol for Colombian cutaneous leishmaniasis: a randomized, controlled trial. Ann Intern Med 1997; 126:232-6.
8. Urbina JA. Lipid biosynthesis pathways as chemotherapeutic targets in kinetoplastid parasites. Parasitology 1997; 114(Suppl):S91-9.
9. Croft SL, Neal RA, Pendergast W, et al. The activity of alkylphosphorylcholines and related derivatives against Leishmania donovani. Biochem Pharmacol 1987; 36:2633-6.
10. Kuhlencord A, Maniera T, Eibl H, et al. Hexadecylphosphocholine: oral treatment of visceral leishmaniasis in mice. Antimicrob Agents Chemother 1992; 36:1630-4.
11. Sundar S, Rosenkaimer K, Makharia MK, et al. Trial of oral miltefosine for visceral leishmaniasis. Lancet 1998; 352:1821-3.
12. Jha TK, Sundar S, Thakur CP, et al. Miltefosine, an oral agent, for the treatment of Indian visceral leishmaniasis. N Engl J Med 1999; 341:1795-800.
13. Sundar S, Jha TK, Thakur CP, et al. Oral miltefosine for Indian visceral leishmaniasis. N Engl J Med 2002; 347:1739-46.
14. Bhattacharya SK, Jha TK, Sundar S, et al. Efficacy and tolerability of miltefosine for childhood visceral leishmaniasis in India. Clin Infect Dis 2004; 38:217-21.
15. Jha TK, Olliaro P, Thakur CP, et al. Randomised controlled trial of aminosidine (paromomycin) v sodium stibogluconate for treating visceral leishmaniasis in North Bihar, India. BMJ 1998; 316:1200-5.
16. Soto J, Grogl M, Berman J, Olliaro P. Limited efficacy of injectable aminosidine as single-agent therapy for Colombian cutaneous leishmaniasis. Trans R Soc Trop Med Hyg 1994; 88:695-8.
17. Hepburn NC, Tidman MJ, Hunter JA. Aminosidine (paromomycin) versus sodium stibogluconate for the treatment of American cutaneous leishmaniasis. Trans R Soc Trop Med Hyg 1994; 88:700-3.
18. Soto J, Toledo J, Gutierrez P, et al. Treatment of American cutaneous leishmaniasis with miltefosine, an oral agent. Clin Infect Dis 2001; 33:E57-61.
19. Noyes HA, Belli AA, Miangon R. Appraisal of various random amplified polymorphic DNA-polymerase chain reaction primers for Leishmania identification. Am J Trop Med Hyg 1996; 55:98-105.
20. Noyes HA, Reyburn H, Bailey JW, Smith D. A nested-PCR-based schizodeme method for identifying Leishmania kinetoplast minicircle classes directly from clinical samples and its application to the study of the epidemiology of Leishmania tropica in Pakistan. J Clin Microbiol 1998; 36:2877-81.
21. Soto-Mancipe J, Grogl M, Berman JD. Evaluation of pentamidine for the treatment of cutaneous leishmaniasis in Colombia. Clin Infect Dis 1993; 16:417-25.
22. Soto J, Fuya P, Herrera R, Berman J. Topical paromomycin/ methylbenzethonium chloride plus parenteral meglumine antimonate as treatment for American cutaneous leishmaniasis: controlled study. Clin Infect Dis 1998; 26:56-8.
23. Navin TR, Arana BA, Arana FE, Berman JD, Chajon JF. Placebo-controlled clinical trial of sodium stibogluconate (Pentostam) versus ketoconazole for treating cutaneous leishmaniasis in Guatemala. J Infect Dis 1992; 165:528-34.
24. Navin TR, Arana BA, Arana FE, de Merida AM, Castillo AL, Pozuelos JL. Placebo-controlled clinical trial of meglumine antimonate (glucantime) vs localized controlled heat in the treatment of cutaneous leishmaniasis in Guatemala. Am J Trop Med Hyg 1990; 42:43-50.
25. Herwaldt BL, Arana BA, Navin TR. The natural history of cutaneous leishmaniasis in Guatemala. J Infect Dis 1992; 165:518-27.
26. Soto J, Buffet P, Grogl M, Berman J. Successful treatment of Colombian cutaneous leishmaniasis with four injections of pentamidine. Am J Trop Med Hyg 1994; 50:107-11.
27. Sampaio SAP, Castro RM, Dillon NL, Martins JEC. Treatment of mucocutaneous (American) leishmaniasis with amphotericin B: report of 70 cases. Int J Dermatol 1971; 10:179-81.
28. Alrajhi AA, Ibrahim EA, De Vol EB, Khairat M, Faris RM, Maguire JH. Fluconazole for the treatment of cutaneous leishmaniasis caused by Leishmania major. N Engl J Med 2002; 346:891-5.